Opaleye Management Inc. Nuvalent, Inc. Transaction History
Opaleye Management Inc.
- $508 Million
- Q4 2024
A detailed history of Opaleye Management Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 58,500 shares of NUVL stock, worth $4.21 Million. This represents 0.9% of its overall portfolio holdings.
Number of Shares
58,500
Previous 64,000
8.59%
Holding current value
$4.21 Million
Previous $6.55 Million
30.06%
% of portfolio
0.9%
Previous 1.2%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
232Shares Held
59MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.3 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$386 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$324 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$218 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$189 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.09B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...